Eli Lilly CDR (CAD Hedged)
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10000
- Registration Number
- NCT06383390
- Locations
- ๐บ๐ธ
Alabama Kidney Research, Alabaster, Alabama, United States
๐บ๐ธCentral Research Associates, Birmingham, Alabama, United States
๐บ๐ธAlliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- ๐บ๐ธ
Velocity Clinical Research, Gardena, Gardena, California, United States
๐บ๐ธIrvine Clinical Research, Irvine, California, United States
๐บ๐ธVelocity Clinical Research, Westlake, Los Angeles, California, United States
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 112
- Registration Number
- NCT06370715
- Locations
- ๐ฎ๐ณ
Osmania Medical College & Hospital, Hyderabad, Andhra Pradesh, India
๐ฎ๐ณKing George Hospital, Visakhapatnam, Visakhapatnam, Andhra Pradesh, India
๐ฎ๐ณDiabetes Research Centre, Royapuram, Chennai India, India
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06370728
- Locations
- ๐บ๐ธ
ICON Early Phase Services, San Antonio, Texas, United States
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT06362265
- Locations
- ๐บ๐ธ
Honor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธChildren's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธChildren's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia, United States
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT06354660
- Locations
- ๐บ๐ธ
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
๐บ๐ธTucson Clinical Research Institute, Tucson, Arizona, United States
๐บ๐ธSan Fernando Valley Health Institute, Canoga Park, California, United States
A Study of LY3841136 in Overweight and Obese Participants
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT06345066
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06342596
- Locations
- ๐ฌ๐ง
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 510
- Registration Number
- NCT06338995
- Locations
- ๐บ๐ธ
AllerVie Clinical Research, Birmingham, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธKeck Medicine of USC, Arcadia, California, United States
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
- Conditions
- Perennial Allergic Rhinitis (PAR)
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06339008
- Locations
- ๐บ๐ธ
Allergy and Asthma Specialists Medical Group, Huntington Beach, California, United States
๐บ๐ธ310 Clinical Research, Inglewood, California, United States
๐บ๐ธAllergy & Asthma Associates of Southern California dba. Southern California Research, Laguna Niguel, California, United States